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Tetradecanoyl phorbol acetate (TPA) stimulates growth hormone (GH) and prolactin secretion from ovine anterior pitui- 
tary cells. Pretreatment of the cells with TPA abolishes this effect, presumably due to down-regulation of protein kinase 
C. Such pretreatment did not alter effects of thyrotropin-releasing hormone or dopamine on prolaction secretion, suggest- 
ing no involvement of protein kinase C. Pretreatment with TPA attenuated actions of GH-releasing hormone on GH 
release (but not actions on cyclic AMP levels), possibly due to depletion of cellular stores of GH. Such pretreatment 
also attenuated inhibition of GH release by somatostatin, possibly due to phosphorylation of receptors or associated 
proteins by protein kinase C. 
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1. INTRODUCTION 
Secretion of growth hormone (GH) and prolac- 
tin from anterior pituitary cells is under the control 
of hypothalamic factors. GH secretion is 
stimulated by GH-releasing hormone (GHRH) and 
inhibited by somatostatin, while prolactin secre- 
tion is stimulated by thyrotropin releasing hor- 
mone (TRH) and inhibited by dopamine. Various 
factors appear to play a role in mediating the ac- 
tions of these hypothalamic hormones, including 
cyclic AMP and intracellular [Ca”]. The phorbol 
ester tetradecanoyl phorbol acetate (TPA), which 
increases protein kinase C activity [ 1,2], stimulates 
both prolactin and GH release from anterior 
pituitary cells [3-51. This suggests that protein 
kinase C may also be involved in regulating the 
secretion of these hormones. 
Although short-term treatment with phorbol 
esters is known to activate protein kinase C, in 
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several cell types long-term exposure (3 to 24 h) to 
TPA reduces both the amount and activity of pro- 
tein kinase C to very low levels [6,7]. This selective 
down-regulation of protein kinase C has been 
employed by a number of investigators to deter- 
mine the role of the enzyme in the molecular mode 
of action of hormones [7,8]. 
Recently, Ohmura et al. [9] have shown that a 
short pretreatment with TPA can lead to attenua- 
tion of the stimulatory actions of GHRH on ac- 
tivated rat pituitary cells. Here we have used 
cultured sheep pituitary cells to investigate the ef- 
fects of such down-regulation on responses to 
GHRH and somatostatin (GH secretion) and TRH 
and dopamine (prolactin secretion), and thus the 
role that protein kinase C may play in regulating 
the actions of these factors. 
2. MATERIALS AND METHODS 
2.1. Materials 
Synthetic somatostatin (l-14), GHRH (I-44-NH& 
dopamine, TRH and TPA were obtained from Sigma Chemical 
Co., Poole, England. Sera and culture media were obtained 
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from Gibco, Paisley, Scotland. Ovine GH (NIH-GH-S9) and 
ovine prolactin (NIAMDD-oPrl-14) were gifts from Dr A.E. 
Wilhelmi and the National Institute of Arthritis, Diabetes and 
Digestive and Kidney Diseases, NIH, Bethesda, MD, USA. 
2.2. Preparation and culture of pituitary cells 
Cells were prepared and incubated as in [lo]. Ovine anterior 
pituitary cells were dispersed (60 min, 37’C) using collagenase 
(Boehringer; 1.5 mg/ml), hyaluronidase (Sigma, type-1s; 
0.5 mg/ml), deoxyribonuclease I (Boehringer, grade II; 
0.25 mg/ml) and bovine serum albumin (Sigma, fraction V; 
30 mg/ml) in medium containing NaCl(137 mM), KC1 (5 mM), 
NazHP04 (0.7 mM), glucose (10 mM) and Hepes (25 mM), ad- 
justed to pH 7.4 with NaOH. Cells were collected by centrifuga- 
tion (400 x g for 2 min) and washed 5 times by resuspension i  
the Hepes-buffered medium and centrifugation. The cells were 
pipetted (0.5-1.0 x ld cells/dish) into 3.5 cm culture plates 
(Sterilin) and incubated in Dulbecco’s modified Eagle medium 
(3 ml/dish) containing 25 mM Hepes, 5% fetal calf serum, 
10% horse serum and antibiotics for 72 h at 37°C under 95% 
sir/5% CO2. 
2.3. Experimental incubations 
After 72 h the incubation medium was discarded and the cells 
were washed three times with the incubation medium without 
serum (in which subsequent incubations were also carried out). 
The cells were preincubated for 5 h with or without TPA, 
washed and then incubated for 30 min with or without test 
substances. At the end of the experimental incubation the media 
were centrifuged (400 x g, 2 min) and the supernatants tored 
at -20°C until assayed for hormone content. The cellular 
cyclic nucleotides were extracted with 10% (w/v) trichloroacetic 
acid (2 h at 4’C) and stored frozen at -20°C prior to assay. 
2.4. Assays 
The radioimmunoassay.procedures for ovine GH and prolac- 
tin were based on methods using specific antisera for these hor- 
mones, raised in rabbits, as in [lo]. Hormones were iodinated 
with Na12’I as in [lo]. All samples, standards etc. were dis- 
solved in assay buffer containing sodium phosphate (0.05 M) 
pH 7.6, merthiolate (0.6 mM), bovine serum albumin (O.OSOro) 
and Triton X-100 (O.OSOro). CAMP in cell extracts was 
measured, following acetylation, as in [I 11. 
3. RESULTS 
TPA (100 ng/ml) stimulated secretion of GH 
and prolactin from ovine anterior pituitary cells as 
shown previously [5,12]. Pretreatment of the cells 
with 0.1-1000 ng/ml TPA for 5 h resulted in a 
dose-dependent inhibition of this stimulatory ef- 
fect (fig.1). Pretreatment with 1000 ng/ml TPA 
for 5 h completely inhibited the ability of 
100 ng/ml TPA to stimulate prolactin and GH 
release. 
TRH (100 nM) stimulated prolactin release 
2-3-fold and, as expected, dopamine inhibited this 
stimulated prolactin release (fig.2). Pretreatment 
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Fig. 1. Effects of pretreatment with TPA on the secretion of GH 
(a) and prolactin (b) by sheep pituitary cells stimulated with 
100 ng/ml TPA. Cultured cells were pretreated for 5 h with the 
concentration of TPA shown. Medium was then changed and 
secretion during a 30 min incubation in the presence of 0 or 
100 ng/ml TPA was measured. Values shown are means k SE 
(n = 3). Similar results were obtained in 2 experiments. 
of the pituitary cells with TPA had no significant 
effect on TRH-stimulated prolactin release or the 
ability of dopamine (100 nM) to inhibit TRH- 
stimulated prolactin release. 
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Fig.2. Effects of pretreatment with TPA on the secretion of 
prolactin in response to TRH in the presence or absence of 
dopamine (DA). Cultured ovine pituitary cells were pretreated 
for 5 h with or without 1 fig/ml TPA, as indicated. Medium 
was then changed and secretion was measured uring a 30 min 
incubation in the presence or absence of TPA (100 ng/ml), 
TRH (100 nM) or TRH plus dopamine (100 nM each). Values 
shown are means f SE (n = 3). Similar results were obtained 
in 3 experiments. 
GHRH (1 nM) stimulated GH release 5-lo-fold 
and somatostatin (100 nM) inhibited this (fig.3). 
Pretreatment of the anterior pituitary cells with 
TPA (1000 ng/ml) for 5 h lowered the ability of 
GHRH to stimulate growth hormone release by 
44 -t 5% (n = 12). Somatostatin (100 nM) blocked 
the ability of GHRH to stimulate GH secretion in 
Table 1 
Effects of GHRH with or without TPA pretreatment on CAMP 
levels in cultured ovine pituitary cells 
Pretreatment Experimental CAMP concentration 
treatment (pmol/106 cells) 
30 min, medium control 1.95 f 0.17 
30 min, medium GHRH 10.35 f 0.18 
30 min, TPA GHRH 22.60 f 0.25 
5 h, medium control 1.54 + 0.04 
5 h, TPA control 1.50 f 0.11 
5 h, medium GHRH 6.21 f 0.10 
5 h, TPA GHRH 13.80 f 0.18 
Cells were preincubated for 30 min or 5 h with or without TPA 
(1 rg/ml), and then incubated for 30 min with or without 
GHRH (1 nM). Values shown are means f SE (n = 3). Similar 
results were obtained in 3 experiments 
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Fig.3. Effects of pretreatment with TPA on the secretion of GH 
in response to GHRH in the presence or absence of 
somatostatin (SS). Cultured ovine pituitary cells were 
pretreated for 5 h with or without 1 pg/ml TPA, as indicated. 
Medium was then changed and secretion was measured uring 
a 30 min incubation in the presence or absence of TPA 
(100 ng/ml), GHRH (1 nM) or GHRH (1 nM) plus 
somatostatin (100 nM). Values shown are means + SE (n = 3). 
Similar results were obtained in 4 experiments. 
cultured pituitary cells (fig.3), but this effect was 
markedly attenuated in cells that had been 
pretreated with TPA. 
The total cellular content of GH was reduced by 
78 + 7% (n = 6) by TPA pretreatment, which 
could underlie the decreased secretory response. 
TPA pretreatment had no significant effect on 
basal CAMP levels, but led to significantly en- 
hanced stimulation of CAMP concentration by 
GHRH (table 1). Somatostatin had no effect on 
CAMP levels, irrespective of TPA pretreatment, in 
accordance with previous results in ovine pituitary 
cells [12,13]. 
4. DISCUSSION 
Pituitary protein kinase C has been well 
characterized [14,151. The down-regulation of this 
enzyme on prolonged exposure to TPA has been 
observed in many tissues and may be due to its pro- 
teolytic degradation [6]. In rat pituitary tumour 
cell lines (GH cells), binding of TRH to its receptor 
results in activation of phospholipase C and the 
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generation of inositol trisphosphate and 
diacylglycerol [ 161, probably leading to a rapid rise 
in intracellular free [Ca’+] causing an initial peak 
of prolactin release [16,17], and activation of pro- 
tein kinase C giving a more-sustained release of the 
hormone [3,16,18,19]. 
That protein kinase C plays a part in mediating 
the actions of TRH on prolactin secretion in nor- 
mal pituitary cells is less clearly established. TPA 
does stimulate prolactin secretion (fig.1) and the 
effect is abolished by pretreatment with TPA. 
However, TPA pretreatment did not attenuate the 
stimulation of prolactin secretion caused by TRH 
(fig.2), suggesting that in this sheep pituitary cell 
system protein kinase C is not involved in 
mediating the effects of this peptide. 
The role of protein kinase C in the mode of ac- 
tion of GHRH is unclear. GHRH and TPA have 
an additive effect on GH secretion, indicating that 
they may act via independent stimulatory 
pathways [4,20]. Pretreatment with TPA at- 
tenuated the action of GHRH on GH secretion, in 
agreement with studies on rat pituitary cells [9]. 
This could be due to down-regulation of protein 
kinase C, but it seems more likely that the large 
depletion of the cellular content of GH caused by 
TPA pretreatment results in a reduced pool of 
releasable GH and a decreased response to GHRH. 
The observation that TPA pretreatment did not 
decrease the ability of GHRH to stimulate CAMP 
levels in these experiments (table 1) tends to sup- 
port such a conclusion. In fact TPA pretreatment 
increased the effects of GHRH on intracellular 
CAMP levels, possibly due to the activation of pro- 
tein kinase C prior to its down-regulation. This 
observation contrasts with results obtained with 
rat pituitary cells [9] where TPA-pretreatment led 
to a decreased stimulation of CAMP levels in 
response to GHRH. 
The ability of TPA pretreatment to block partly 
the inhibition by somatostatin of GHRH- 
stimulated GH release (fig.3) is striking. It is 
unlikely to be due to depletion of cellular GH con- 
tent or to mediation of the inhibitory actions of 
somatostatin by protein kinase C, given that short- 
term treatment with TPA stimulates GH release. 
Possibly activation of protein kinase C (prior to 
down-regulation) leads to phosphorylation of the 
somatostatin receptor or some component of the 
associated effector system. Preliminary observa- 
102 
tions have indicated that a short preincubation 
(30 min) with TPA leads to a greater attenuation 
of the inhibitory effect of somatostatin, which 
would agree with such a mechanism. An inhibitory 
effect of TPA on binding of somatostatin has been 
observed previously for the pancreatic somatostat- 
in receptor [21]. It is notable that TPA pretreat- 
ment did not significantly block the ability of 
dopamine to inhibit TRH-stimulated prolactin 
release. 
In conclusion, the experiments presented here 
gave no indication that prolonged pretreatment 
with TPA altered the ability of sheep anterior 
pituitary cells to respond to TRH or dopamine, ac- 
ting on prolactin secretion. This suggests that pro- 
tein kinase C is not involved as a mediator or 
modulator of the actions of these factors. TPA 
pretreatment did lead to decreased stimulation of 
GH secretion by GHRH, but this could be due to 
depletion of cellular GH stores. Pretreatment with 
TPA partially blocked the inhibition of GHRH- 
stimulated secretion by somatostatin, possibly 
because treatment with TPA activates protein 
kinase C prior to down-regulation, and the enzyme 
phosphorylates and partially inactivates the recep- 
tors and/or effector systems for somatostatin. 
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